Company Profiles

driven by the PitchBook Platform

Epiphany Biosciences

Epiphany Biosciences
2006 FOUNDED
OOB STATUS
Out of Business LATEST DEAL TYPE
Description

Developer of antiviral therapeutics to to prevent the spread of varicella zoster virus (VZV), epstein-barr virus (EBV) and hepatitis C virus (HCV).

Ownership Status
Out of Business
Financing Status
Formerly VC-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
One California Street
Suite 2800
San Francisco, CA 94111
United States

+1 (415) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Epiphany Biosciences’s full profile, request a free trial.

Epiphany Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Nov-2016 000.00 Completed Out of Business
1. Early Stage VC (Series A) 14-Mar-2007 000.00 000.00 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Epiphany Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Epiphany Biosciences Executive Team (4)

Name Title Board
Seat
Contact
Info
Fred Volinsky MD Chief Executive Officer, Co-Founder and Chairman
Michael Houghton Chief Scientific Officer
Brian Murphy Chief Medical Officer
Steve Blank Co-Founder
Questions or concerns about this profile? Reach out to website-support@pitchbook.com